Aeolus is developing a new class of that protect healthy tissue from the damaging effects of oxidative stress. Its first compound, AEOL 10150 is being developed as a medical countermeasure against the pulmonary effects of Acute Radiation Syndrome (“Lung-ARS”) and the delayed effects of acute radiation exposure (“DEARE”) under a contract with the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the United States Department of Health and Human Services (“HHS”). The total value of the contract with all options is $118.4 million

from http://www.aolsrx.com/about

Research Grants 3 show all


$100K
2003

$375K
2004

$375K
2005

Patents 84show all

  • 56
    A61K - Preparations for medical, dental, or toilet purposes
  • 54
    C07D - Heterocyclic compounds
  • 20
    C09B - Organic dyes or closely-related compounds for producing dyes
  • 11
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 3
    C12N - Microorganisms or enzymes
  • 2
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 2
    B82Y - Specific uses or applications of nanostructures
  • 2
    C01C - Ammonia
  • 1
    A01K - Animal husbandry
  • 1
    C07K - Peptides

SEC Filings show all


94
8-K

43
10-Q

14
10-K

8
D

1
S-1

Contact Information

Research Triangle Park, NC
United States

SEC Form D Funding Events

DateOfferedSoldType
2013-03-06$3,615,500$3,615,500Equity, Security to be Acquired
2012-04-18$690,050$690,050Equity, Option to Acquire, Security to be Acquired
2010-08-19$2,000,000$1,000,000Equity, Option to Acquire, Security to be Acquired
2010-08-09$3,300,000$3,300,000Equity, Option to Acquire, Security to be Acquired
2009-11-23$3,300,000$1,650,000Equity, Option to Acquire, Security to be Acquired
2009-04-06$1,500,000$1,500,000Equity, Option to Acquire, Security to be Acquired
2008-08-06Unknown Unknown Other (Paper Filing)

Key Executives

  • John McManus
    Executive Officer
  • Brian Day
    Executive Officer
  • Michael McManus
    Executive Officer
  • David Cavalier
    Director
  • John Farah
    Director
  • Joseph Krivulka
    Director
  • Amit Kumar
    Director
  • Michael Lewis
    Director
  • Chris Rallis
    Director
  • Peter Suzdak
    Director
  • John L. Mcmanus
    Executive Officer
  • Russell Skibsted
    Executive Officer
  • David C. Cavalier
    Director
  • Joseph J. Krivulka
    Director
  • Chris A. Rallis
    Director
  • John M. Farah, Jr.
    Director
  • Michael E. Lewis
    Director
  • Peter D. Suzkak
    Director